Sionna advances SION-451 and SION-2222 into Phase 2a trial to test dual-corrector approach for Trikafta-resistant CF patients ...
Compass Pathways' 52-week COMP360 data shows 40-45% response rates in treatment-resistant depression. FDA approval in 2027 means nothing without ...
From exon 20 insertions to subcutaneous delivery and inclusive trial design, Joshua Bauml explains why the biology demanded a ...
Definium's DT120 ODT met its primary endpoint in Phase 3 testing for generalized anxiety disorder, potentially offering an alternative to decades-old SSRI and S ...
Ivonescimab beats pembrolizumab on survival in first-line PD-L1-positive NSCLC, extending median OS by over eight months in Phase III trial.
Supply management and vendor accountability determine IRT trial success for biotech sponsors. YPrime's guide identifies critical cost exposure points and evalua ...
Researchers commonly misread IRB review pathways, causing study delays. Understanding exemption categories and expedited eligibility prevents protocol cycling.
MRI surveillance alone reduced cognitive failure risk by 40% versus MRI plus radiation in SCLC patients, per phase III ...
Amivantamab plus chemotherapy achieves 34.3-month median overall survival in EGFR exon 20 insertion lung cancer, doubling ...
Tam-Peli extends median survival to 13.3 months in relapsed small-cell lung cancer, a significant improvement over topotecan ...
Trastuzumab Botidotin Phase 3 trial shows 11.1-month PFS versus 4.4 months with T-DM1 in HER2-positive breast cancer, with ...
Phase's AI clinical data platform promises smarter trial design, but before sponsors add another vendor, the activation-cycle ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results